Health Care • Biotechnology: Pharmaceutical Preparations
$9.52 ▼ -0.30
(-3.05%)
MKT CAP: $513.4M • VOL: 196.5K
52W L $5 52W H $10
ROARABLE / RQD
E • 34/100
PIOTROSKI
2 / 9
DMAC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$34.4M | -$26.7M | -$21.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$32.8M | -$24.4M | -$19.4M |
| EBITDA (Normalized) | -$34.4M | -$26.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$29.1M | -$22.1M | -$18.7M |
| Capital Expenditures (CapEx) | $40.0K | $25.0K | — |
| Free Cash Flow (FCF) | -$29.1M | -$22.1M | -$18.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $15.6M | $3.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $56.1M | $40.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DMAC.